Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.32 |
| ▸ | SLC6A12 | P48065 | 3/20 | 0.31 |
| ▸ | SLC6A11 | P48066 | 3/20 | 0.31 |
| ▸ | SLC6A13 | Q9NSD5 | 3/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1924098 | 1.00 | EPHX2 (0.41) | EPHX2NR1H2SLC6A12SLC6A11SLC6A13 | |
| SCHEMBL8901151 | 0.80 | TDP1 (0.39) | TDP1 | |
| SCHEMBL1897777 | 0.79 | TDP1 (0.42) | SLC6A12SLC6A11SLC6A13TDP1 | |
| SCHEMBL24258352 | 0.78 | SLC6A12 (0.30) | SLC6A12SLC6A11SLC6A13 | |
| SCHEMBL17294420 | 0.77 | — | — | |
| SCHEMBL17831709 | 0.77 | SLC6A12 (0.42) | EPHX2NR1H2SLC6A12SLC6A11SLC6A13 | |
| SCHEMBL13940976 | 0.75 | EPHX2 (0.41) | EPHX2NR1H2TDP1 | |
| SCHEMBL11683426 | 0.75 | ALOX5 (0.45) | TDP1 | |
| SCHEMBL17831720 | 0.75 | EPHX2 (0.38) | EPHX2NR1H2SLC6A12SLC6A11SLC6A13 | |
| SCHEMBL1923310 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101778820-B | Benzoyl-piperidine derivatives as dual modulators of the 5-ht2a and d3 receptors | HOFFMANN LA ROCHE | 2012-12-05 | — | — | CN | claimed |
| US-8097637-B2 | Benzoyl-piperidine derivatives as dual modulators of the 5-HT2A and D3 receptors | HOFFMANN-LA ROCHE INC. (US) | 2012-01-17 | — | — | US | claimed |
| EP-2185513-B1 | BENZOYL-PIPERIDINE DERIVATIVES AS DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS | HOFFMANN LA ROCHE (CH) | 2011-06-08 | — | — | EP | claimed |
| EP-2185513-A1 | BENZOYL-PIPERIDINE DERIVATIVES AS DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS | F. Hoffmann-Roche AG (CH) | 2010-05-19 | — | — | EP | claimed |
| WO-2009019174-A1 | BENZOYL-PIPERIDINE DERIVATIVES AS DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-12 | — | — | WO | claimed |
| US-20090042943-A1 | BENZOYL-PIPERIDINE DERIVATIVES AS DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS | HOFFMANN-LA ROCHE, INC. | 2009-02-12 | — | — | US | claimed |
| WO-2025045233-A1 | MACROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR, AND USE THEREOF | 劲方医药科技(上海)股份有限公司 | 2025-03-06 | — | — | WO | disclosed |
| CN-101778820-B | Benzoyl-piperidine derivatives as dual modulators of the 5-ht2a and d3 receptors | HOFFMANN LA ROCHE | 2012-12-05 | — | — | CN | disclosed |
| US-8097637-B2 | Benzoyl-piperidine derivatives as dual modulators of the 5-HT2A and D3 receptors | HOFFMANN-LA ROCHE INC. (US) | 2012-01-17 | — | — | US | disclosed |
| CN-102159557-A | Piperazine d3 and 5-ht2a receptor modulators | HOFFMANN LA ROCHE | 2011-08-17 | — | — | CN | disclosed |
| EP-2185513-B1 | BENZOYL-PIPERIDINE DERIVATIVES AS DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS | HOFFMANN LA ROCHE (CH) | 2011-06-08 | — | — | EP | disclosed |
| EP-2185513-A1 | BENZOYL-PIPERIDINE DERIVATIVES AS DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS | F. Hoffmann-Roche AG (CH) | 2010-05-19 | — | — | EP | disclosed |
| US-20090042943-A1 | BENZOYL-PIPERIDINE DERIVATIVES AS DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS | HOFFMANN-LA ROCHE, INC. | 2009-02-12 | — | — | US | disclosed |
| WO-2009019174-A1 | BENZOYL-PIPERIDINE DERIVATIVES AS DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042943-A1 | BENZOYL-PIPERIDINE DERIVATIVES AS DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS | HTR2A, HTR3A, HTR5A | EPHX2 2867/4885NR1H2 1245/4885SLC6A12 1882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.